# Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

> **NCT03756454** · PHASE4 · TERMINATED · sponsor: **Michael E Villarreal, MD** · enrollment: 5 (actual)

## Conditions studied

- Clostridia Difficile Colitis
- Clostridium; Sepsis

## Interventions

- **BIOLOGICAL:** Bezlotoxumab
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT03756454
- **Lead sponsor:** Michael E Villarreal, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-19
- **Primary completion:** 2022-05-23
- **Final completion:** 2022-05-23
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Difficulties with enrollment and inability to guarantee further study drug supply after current supply expired.
- **Last updated:** 2023-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03756454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03756454, "Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03756454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*